<DOC>
	<DOCNO>NCT01350141</DOCNO>
	<brief_summary>PF-04950615 new investigational hypercholesterolemic agent test study evaluate low LDL cholesterol .</brief_summary>
	<brief_title>A Multiple Dose Study Of PF-04950615 ( RN316 ) In Subjects On Maximum Doses Of Statins</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Body Mass Index ( BMI ) 18.5 40 kg/m2 On stable maximum daily dose statin , define atorvastatin 80 mg rosuvastatin 40 mg minimum 45 day prior Day 1 . Lipids meet follow criterion twice screen period : Fasting LDL C = &gt; 80 mg/dL ; Fasting TG &lt; 400 mg/dL . History cardiovascular cerebrovascular event procedure ( eg , MI , stroke , TIA , angioplasty ) past year . Poorly control type 1 type 2 diabetes mellitus . Poorly control hypertension . Fasting triglyceride &gt; 400 mg/dL 12 lead ECG demonstrate QTcFF &gt; 455 msec screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>high cholesterol</keyword>
	<keyword>LDL</keyword>
	<keyword>antibody</keyword>
	<keyword>PCSK9</keyword>
	<keyword>PF-04950615</keyword>
	<keyword>RN316</keyword>
</DOC>